Manufacturer copay assistance · Cimerli (Q5128) · Sandoz (license holder Bioeq AG; acquired from Coherus Mar 2024)
$0 · Maximum benefit Contact Cimerli Solutions for maximum benefit details · Covers Cimerli drug cost-share — copay and coinsurance only
Published terms from the manufacturer. Per-patient eligibility is confirmed at enrollment.
This manufacturer program excludes government insurance. Foundation disease funds are the route instead — status shown as of each fund's last verification.
Run a benefits estimate for Cimerli — the program's cap applies against the patient share CareCost calculates.
Yes — Cimerli Solutions Co-Pay Program from Sandoz (license holder Bioeq AG; acquired from Coherus Mar 2024). Eligible patients may pay $0 per injection through Cimerli Solutions. Commercial insurance is required; Medicare and Medicaid patients are not eligible.
Eligible patients may pay $0 per injection through Cimerli Solutions Maximum benefit: Contact Cimerli Solutions for maximum benefit details. Covers Cimerli drug cost-share — copay and coinsurance only
Accepted insurance: commercial. Not eligible: medicare, medicaid, government.